A Shared Pathogenic Mechanism for Valproic Acid and SHROOM3 Knockout in a Brain Organoid Model of Neural Tube Defects

Neural tube defects (NTDs) including anencephaly and spina bifida are common major malformations of fetal development resulting from incomplete closure of the neural tube. These conditions lead to either universal death (anencephaly) or life-long severe complications (spina bifida). Despite hundreds of genetic mouse models having neural tube defect phenotypes, the genetics of human NTDs are poorly understood. Furthermore, pharmaceuticals such as antiseizure medications have been found clinically to increase the risk of NTDs when administered during pregnancy. Therefore, a model that recapitulates human neurodevelopment would be of immense benefit to understand the genetics underlying NTDs and identify teratogenic mechanisms. Using our self-organizing single rosette spheroid (SOSRS) brain organoid system, we have developed a high-throughput image analysis pipeline for evaluating SOSRS structure for NTD-like phenotypes. Similar to small molecule inhibition of apical constriction, the antiseizure medication valproic acid (VPA), a known cause of NTDs, increases the apical lumen size and apical cell surface area in a dose-responsive manner. This expansion was mimicked by GSK3β and HDAC inhibitors; however, RNA sequencing suggests VPA does not inhibit GSK3β at these concentrations. Knockout of SHROOM3, a well-known NTD-related gene, also caused expansion of the lumen as well as reduced f-actin polarization. The increased lumen sizes were caused by reduced cell apical constriction suggesting that impingement of this process is a shared mechanism for VPA treatment and SHROOM3-KO, two well-known causes of NTDs. Our system allows the rapid identification of NTD-like phenotypes for both compounds and genetic variants and should prove useful for understanding specific NTD mechanisms and predicting drug teratogenicity.

[1]  J. Kubanek,et al.  Modeling human telencephalic development and autism-associated SHANK3 deficiency using organoids generated from single neural rosettes , 2022, Nature Communications.

[2]  J. Wallingford,et al.  In vivo high-content imaging and regression analysis reveal non-cell autonomous functions of Shroom3 during neural tube closure. , 2022, Developmental biology.

[3]  Jiao Jiao,et al.  Folic Acid Rescues Valproic Acid-Induced Morphogenesis Inhibition in Neural Rosettes Derived From Human Pluripotent Stem Cells , 2022, Frontiers in Cellular Neuroscience.

[4]  Jun Z. Li,et al.  Self-organizing Single-Rosette Brain Organoids from Human Pluripotent Stem Cells , 2021, bioRxiv.

[5]  E. Siggia,et al.  Human neural tube morphogenesis in vitro by geometric constraints , 2021, Nature.

[6]  Timothy J. Edwards,et al.  Cell non-autonomy amplifies disruption of neurulation by mosaic Vangl2 deletion in mice , 2020, Nature communications.

[7]  B. Niu,et al.  Neural tube defects: role of lithium carbonate exposure in embryonic neural development in a murine model , 2020, Pediatric Research.

[8]  B. Venkatesh,et al.  A loss-of-function NUAK2 mutation in humans causes anencephaly due to impaired Hippo-YAP signaling , 2020, The Journal of experimental medicine.

[9]  R. Green,et al.  Valproate and folate: Congenital and developmental risks , 2020, Epilepsy & Behavior.

[10]  M. Ross,et al.  Loss of RAD9B impairs early neural development and contributes to the risk for human spina bifida , 2020, Human Mutation.

[11]  M. Berthold,et al.  Development of a neural rosette formation assay (RoFA) to identify neurodevelopmental toxicants and to characterize their transcriptome disturbances , 2019, Archives of Toxicology.

[12]  G. Norman,et al.  Limitations of Animal Studies for Predicting Toxicity in Clinical Trials: Is it Time to Rethink Our Current Approach? , 2019 .

[13]  S. Lockman,et al.  Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana. , 2019, The New England journal of medicine.

[14]  N. Greene,et al.  Rho kinase-dependent apical constriction counteracts M-phase apical expansion to enable mouse neural tube closure , 2019, Journal of Cell Science.

[15]  T. Südhof,et al.  Direct Reprogramming of Human Neurons Identifies MARCKSL1 as a Pathogenic Mediator of Valproic Acid-Induced Teratogenicity. , 2019, Cell stem cell.

[16]  Rebecca M Willett,et al.  Engineering induction of singular neural rosette emergence within hPSC-derived tissues , 2018, eLife.

[17]  L. Wan,et al.  Teratogen screening with human pluripotent stem cells. , 2018, Integrative biology : quantitative biosciences from nano to macro.

[18]  F. Luyten,et al.  Folic Acid Exposure Rescues Spina Bifida Aperta Phenotypes in Human Induced Pluripotent Stem Cell Model , 2018, Scientific Reports.

[19]  J. Parent,et al.  Rapid Generation of Human Genetic Loss-of-Function iPSC Lines by Simultaneous Reprogramming and Gene Editing , 2017, Stem cell reports.

[20]  Rolf Bodmer,et al.  High throughput physiological screening of iPSC-derived cardiomyocytes for drug development. , 2016, Biochimica et biophysica acta.

[21]  J. Rahnenführer,et al.  Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests , 2016, Archives of Toxicology.

[22]  Julieta M. Panzica-Kelly,et al.  A Developmental Toxicology Assay Platform for Screening Teratogenic Liability of Pharmaceutical Compounds. , 2016, Birth defects research. Part B, Developmental and reproductive toxicology.

[23]  Russell S Kirby,et al.  Population-based birth defects data in the United States, 2008 to 2012: Presentation of state-specific data and descriptive brief on variability of prevalence. , 2015, Birth defects research. Part A, Clinical and molecular teratology.

[24]  N. Vargesson.  Thalidomide‐induced teratogenesis: History and mechanisms , 2015, Birth defects research. Part C, Embryo today : reviews.

[25]  Guy A Rouleau,et al.  Loss-of-function de novo mutations play an important role in severe human neural tube defects , 2015, Journal of Medical Genetics.

[26]  Huiping Zhu,et al.  Identification of Novel CELSR1 Mutations in Spina Bifida , 2014, PloS one.

[27]  S. Gentile.  Lithium in pregnancy: the need to treat, the duty to ensure safety , 2012, Expert opinion on drug safety.

[28]  R. Stevenson,et al.  Mutations in the planar cell polarity genes CELSR1 and SCRIB are associated with the severe neural tube defect craniorachischisis , 2012, Human mutation.

[29]  L. Winn,et al.  Valproic Acid Increases Formation of Reactive Oxygen Species and Induces Apoptosis in Postimplantation Embryos: A Role for Oxidative Stress in Valproic Acid-Induced Neural Tube Defects , 2011, Molecular Pharmacology.

[30]  Yasuko Matsumura,et al.  A more efficient method to generate integration-free human iPS cells , 2011, Nature Methods.

[31]  M. J. Harris,et al.  An update to the list of mouse mutants with neural tube closure defects and advances toward a complete genetic perspective of neural tube closure. , 2010, Birth defects research. Part A, Clinical and molecular teratology.

[32]  Bai-Lin Wu,et al.  VANGL2 mutations in human cranial neural-tube defects. , 2010, The New England journal of medicine.

[33]  J. Wallingford,et al.  Pax6-dependent Shroom3 expression regulates apical constriction during lens placode invagination , 2010, Development.

[34]  H. Son,et al.  Valproic acid promotes neuronal differentiation by induction of proneural factors in association with H4 acetylation , 2009, Neuropharmacology.

[35]  S. Gregory,et al.  Further evidence for a maternal genetic effect and a sex-influenced effect contributing to risk for human neural tube defects. , 2008, Birth defects research. Part A, Clinical and molecular teratology.

[36]  J. Hildebrand,et al.  Shroom regulates epithelial cell shape via the apical positioning of an actomyosin network , 2005, Journal of Cell Science.

[37]  L. Holmes,et al.  Increased rate of major malformations in offspring exposed to valproate during pregnancy , 2005, Neurology.

[38]  J. Wallingford,et al.  Shroom Induces Apical Constriction and Is Required for Hingepoint Formation during Neural Tube Closure , 2003, Current Biology.

[39]  Steve D. M. Brown,et al.  Mutation of Celsr1 Disrupts Planar Polarity of Inner Ear Hair Cells and Causes Severe Neural Tube Defects in the Mouse , 2003, Current Biology.

[40]  Ping Zhu,et al.  Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells , 2001, The EMBO journal.

[41]  P Smith,et al.  Concordance of the toxicity of pharmaceuticals in humans and in animals. , 2000, Regulatory toxicology and pharmacology : RTP.

[42]  Philippe Soriano,et al.  Shroom, a PDZ Domain–Containing Actin-Binding Protein, Is Required for Neural Tube Morphogenesis in Mice , 1999, Cell.

[43]  H. Nau,et al.  Valproic acid-induced neural tube defects in mouse and human: aspects of chirality, alternative drug development, pharmacokinetics and possible mechanisms. , 1991, Pharmacology & toxicology.

[44]  J. Opitz,et al.  Teratogenicity of anticonvulsant drugs. , 1985, American journal of medical genetics.

[45]  G. Windham,et al.  Neural tube defects among twin births. , 1982, American journal of human genetics.

[46]  J. Warkany,et al.  Attempted abortion with aminopterin (4-amino-pteroylglutamic acid); malformations of the child. , 1959, A.M.A. journal of diseases of children.

[47]  H. Evans,et al.  Production of multiple congenital abnormalities in young by maternal pteroylglutamic acid deficiency during gestation. , 1952, The Journal of nutrition.